Overall Survival (OS) in COLUMBUS: A Phase-III-Study with Encorafenib (ENCO) plus Binimetinib (BINI) versus Vemurafenib (VEM) or ENCO in BRAF mutant Melanoma

被引：0
|
作者：
Dummer, R. [1 ]
Ascierto, P. A. [2 ]
Gogas, H. J. [3 ]
Arance, A. [4 ]
Mandala, M. [5 ,6 ]
Liszkay, G. [7 ]
Garbe, C. [8 ]
Schadendorf, D. [9 ]
Krajsova, I [10 ,11 ]
Gutzmer, R. [12 ]
Chiarion-Sileni, V [13 ]
Dutriaux, C. [14 ]
de Groot, J. W. B. [15 ]
Yamazaki, N. [16 ]
Loquai, C. [17 ]
Moutouh-de Parseval, L. A. [18 ]
Pickard, M. D. [19 ]
Sandor, V [19 ]
Robert, C. [20 ]
Flaherty, K. T. [21 ]
机构：
[1] Univ Klinikum Zurich, Zurich, Switzerland
[2] IRCCS Fdn Pascale, Inst Nazl Tumori, Neapel, Italy
[3] Natl & Kapodistrian Univ Athen, Laikon Krankenhaus, Athens, Greece
[4] Klinikum Barcelona, Barcelona, Spain
[5] Papa Giovanni XXIII Krankenhaus, Bergamo, Italy
[6] Tumorzentrum, Bergamo, Italy
[7] Natl Inst Onkol, Budapest, Hungary
[8] Univ Klinikum Tubingen, Tubingen, Germany
[9] Univ Klinikum Essen, Essen, Germany
[10] Karls Univ, Univ Klinikum Prag, Prague, Czech Republic
[11] Karls Univ, Med Fak 1, Prague, Czech Republic
[12] Hannover Med Sch, Hannover, Germany
[13] IRCCS, Onkol Inst Venetien, Padua, Italy
[14] Ctr Hosp Univ Bordeaux, Hop St Andre, Bordeaux, France
[15] Isala, Zwolle, Netherlands
[16] Natl Tumorzentrum Tokyo, Tokyo, Japan
[17] Johannes Gutenberg Univ Mainz, Univ Med, Mainz, Germany
[18] Novartis Pharma AG, Basel, Switzerland
[19] Array BioPharma Inc, Boulder, CO USA
[20] Gustave Roussy, Villejuif, France
[21] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2018年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P44
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [1] Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
    Dummer, Reinhard
    Ascierto, Paolo Antonio
    Gogas, Helen
    Arance, Ana M.
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsova, Ivana
    Gutzmer, Ralf
    Chiarion-Sileni, Vanna
    Dutriaux, Caroline
    de Groot, Jan Willem
    Yamazaki, Naoya
    Loquai, Carmen
    De Parseval, Laure A.
    Pickard, Michael D.
    Sandor, Victor
    Robert, Caroline
    Flaherty, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
    Gogas, Helen
    Ascierto, Paolo Antonio
    Flaherty, Keith
    Arance, Ana
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsova, Ivana
    Gutzmer, Ralf
    de Groot, Jan Willem
    Dutriaux, Caroline
    Loquai, Carmen
    Gollerkeri, Ashwin
    Pickard, Michael D.
    Robert, Caroline
    Dummer, Reinhard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
    Liszkay, Gabriella
    Gogas, Helen
    Mandala, Mario
    Fernandez, Ana Maria Arance
    Garbe, Claus
    Schadendorf, Dirk
    Dummer, Reinhard
    Ascierto, Paolo Antonio
    Robert, Caroline
    Pickard, Michael D.
    Sandor, Victor
    Gollerkeri, Ashwin
    Flaherty, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Update on overall survival in COLUMBUS: A randomised phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma
    Haydon, Andrew
    Liszkay, Gabriella
    Gogas, Helen J.
    Mandala, Mario
    Arance, Ana
    Garbe, Claus
    Dummer, Reinhard
    Ascierto, Paolo A.
    Robert, Caroline
    Pickard, Michael D.
    Sandor, Victor
    Gollerkeri, Ashwin
    Flaherty, Keith T.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 171 - 172
  • [5] Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
    Arance, A.
    Dummer, R.
    Ascierto, P. A.
    Gogas, H.
    Mandala, M.
    Liszkay, G.
    Garbe, C.
    Schadendorf, D.
    Krajsova, I.
    Gutzmer, R.
    Sileni, V. Chiarion
    Dutriaux, C.
    de Groot, J. W. B.
    Yamazaki, N.
    Loquai, C.
    de Parseval, L. A.
    Pickard, M.
    Sandor, V.
    Robert, C.
    Flaherty, K. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma
    Gogas, H.
    Dummer, R.
    Ascierto, P. A.
    Arance, A.
    Mandala, M.
    Liszkay, G.
    Garbe, C.
    Schadendorf, D.
    Krajsova, I.
    Gutzmer, R.
    Sileni, V. Chiarion
    Dutriaux, C.
    de Groot, J. W. B.
    Yamazaki, N.
    Loquai, C.
    de Parseval, L. A.
    Pickard, M.
    Sandor, V.
    Robert, C.
    Flaherty, K. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
    Berking, Carola
    Ascierto, Paolo A.
    Gogas, Helen J.
    Arance, Ana
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsova, Ivana
    Gutzmer, Ralf
    Sileni, Vanna Chiarion
    Dutriaux, Caroline
    de Groot, Jan Willem B.
    Yamazaki, Naoya
    Loquai, Carmen
    de Parseval, Laure A.
    Pickard, Michael
    Sandor, Victor
    Robert, Caroline
    Flaherty, Keith T.
    Dummer, Reinhard
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 45 - 45
  • [8] Update on Overall Survival in the COLUMBUS Study: A randomized Phase 3 Study of Encorafenib (ENCO) plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in Patients with BRAF V600 mutated Melanoma
    Schadendorf, D.
    Garbe, C.
    Gutzmer, R.
    Loquai, C.
    Fluck, M.
    Kiecker, F.
    Mohr, P.
    Terheyden, P.
    Gogas, H. J.
    Ascierto, P. A.
    Flaherty, K. T.
    Arance, A.
    Mandala, M.
    Liszkay, G.
    Krajsova, I.
    de Groot, J. W. B.
    Dutriaux, C.
    Gollerkeri, A.
    Pickard, M. D.
    Robert, C.
    Dummer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 79 - 80
  • [9] Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma
    Dummer, Reinhard
    Ascierto, Paolo A.
    Gogas, Helen J.
    Arance, Ana
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsovÿ, Ivana
    Gutzmer, Ralf
    Sileni, Vanna Chiarion
    Dutriaux, Caroline
    de Groot, Jan Willem B.
    Yamazaki, Naoya
    Loquai, Carmen
    de Parseval, Laure A.
    Pickard, Michael
    Sandor, Victor
    Berking, Carola
    Robert, Caroline
    Flaherty, Keith T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 12 - 13
  • [10] 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) plus binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
    Dummer, R.
    Flaherty, K. T.
    Robert, C.
    Arance, A.
    De Groot, J. W. B.
    Garbe, C.
    Gogas, H. J.
    Gutzmer, R.
    Krajsova, I.
    Liszkay, G.
    Loquai, C.
    Mandala, M.
    Schadendorf, D.
    Yamazaki, N.
    Zohren, F.
    Edwards, M.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S872 - S873
12345